Skip to main content
Terug
INBX logo

Inhibrx Biosciences, Inc.

Datakwaliteit: 100%
INBX
NASDAQ Healthcare Biotechnology
€ 63,12
▼ € 1,51 (-2,34%)
Marktkapitalisatie: 922,00M
Dagbereik
€ 59,98 € 63,39
52-Weeksbereik
€ 10,81 € 94,57
Volume
242.172
50D / 200D Gem.
€ 75,51 / € 51,38
Vorige Slotkoers
€ 64,63

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -6,6 0,4
P/B 115,4 2,9
ROE % -197,9 3,9
Net Margin % -10773,5 3,8
Rev Growth 5Y % -34,6 10,0
D/E 13,4 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,75
€ 1,75 – € 1,75
190 M 1
FY2029 € 0,22
€ 0,22 – € 0,22
130 M 1
FY2028 -€ 0,95
-€ 0,95 – -€ 0,95
98 M 1

Belangrijkste Punten

Revenue declined -34,64% annually over 5 years
Earnings declined -108,30% over the past year
Debt/Equity of 13,39 — high leverage
Negative free cash flow of -129,83M
PEG of 0,08 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 584,64%

Groei

Revenue Growth (5Y)
-34,64%
Revenue (1Y)550,00%
Earnings (1Y)-108,30%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-197,85%
ROIC-88,06%
Net Margin-10773,46%
Op. Margin-10386,54%

Veiligheid

Debt / Equity
13,39
Current Ratio3,93
Interest Coverage-11,07

Waardering

P/E Ratio
-6,58
P/B Ratio115,35
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 550,00% Revenue Growth (3Y) -15,02%
Earnings Growth (1Y) -108,30% Earnings Growth (3Y) N/A
Revenue Growth (5Y) -34,64% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,30M Net Income (TTM) -140,06M
ROE -197,85% ROA -95,62%
Gross Margin -91,00% Operating Margin -10386,54%
Net Margin -10773,46% Free Cash Flow (TTM) -129,83M
ROIC -88,06% FCF Growth (3Y) N/A
Safety
Debt / Equity 13,39 Current Ratio 3,93
Interest Coverage -11,07 Dividend Yield 0,00%
Valuation
P/E Ratio -6,58 P/B Ratio 115,35
P/S Ratio 709,23 PEG Ratio 0,08
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 922,00M Enterprise Value 904,79M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,30M 200.000,0 1,80M 2,19M 7,13M
Net Income -140,06M 1,69B -241,36M -145,23M -81,77M
EPS (Diluted) -9,04 116,58 -5,12 -3,62 -2,15
Gross Profit -1,18M -2,09M 609.000,0 -107,99M 4,44M
Operating Income -135,03M -331,45M -219,22M -129,12M -76,56M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 146,48M 180,77M 307,89M 290,88M 150,45M
Total Liabilities 138,49M 47,18M 264,39M 232,82M 98,07M
Shareholders' Equity 7,99M 133,58M 43,50M 58,06M 52,38M
Total Debt 107,01M 8,05M 210,14M 207,10M 72,14M
Cash & Equivalents 124,22M 152,60M 277,92M 273,87M 131,30M
Current Assets 132,83M 160,40M 295,36M 280,49M 139,11M
Current Liabilities 33,80M 40,73M 56,31M 27,58M 22,45M